EMT-activated secretory and endocytic vesicular trafficking programs underlie a vulnerability to PI4K2A antagonism in lung cancer is a research paper published in Journal of Clinical Investigation (2023). On theSindex it has a DataRank of 0. It has been cited 21 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Institutes of Health
Grant: R01CA236781
National Institutes of Health
Grant: R01 CA2111125
Lung Cancer Research Foundation
Grant: Lung Cancer Research Foundation
NCI NIH HHS
Grant: R01 CA255021
NCI NIH HHS
Grant: K99 CA249048
NCI NIH HHS
Grant: R01 CA211125
NCI NIH HHS
Grant: R00 CA249048
National Institutes of Health
Grant: 5R01CA236781-04
Regulation of lung cancer growth and metastasis by an actionable driver of vesicle biogenesis in the Golgi
National Institutes of Health
Grant: 5R01CA255021-05
A pro-metastatic secretory pathway activated by p53 loss in lung cancer
FWCI
3.95
Citation Percentile
0.9%
Citation Trend
Fields of Study
MeSH Terms
Keywords